Mizuho Securities Downgrades Myriad Genetics (MYGN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Goldman Sachs Downgrades Myriad Genetics (MYGN) to Neutral Following SCOTUS Case
December 3, 2012 9:27 AM ESTGoldman Sachs downgraded Myriad Genetics (NASDAQ: MYGN) from Buy to Neutral with a price target of $26.00 (from $34.00) after the Supreme Court of the United States (SCOTUS) agreed to hear the case against the company relating to the patentability of genes.
Given... More
